Quoc-Bao D. Nguyen, Caroline T. Starling & Adelaide A. Hebert. (2020) The Use of TNFα Inhibitors in Treating Pediatric Skin Disorders. Pediatric Drugs 22:3, pages 311-319.
Crossref

Hakim Ben Abdallah, Karsten Fogh & Rikke Bech. (2019) Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review. International Wound Journal 16:2, pages 511-521.
Crossref

Afsaneh Alavi, Lars E. French, Mark D. Davis, Alain Brassard & Robert S. Kirsner. (2017) Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. American Journal of Clinical Dermatology 18:3, pages 355-372.
Crossref

Stephan R. Vavricka, Alain Schoepfer, Michael Scharl, Peter L. Lakatos, Alexander Navarini & Gerhard Rogler. (2015) Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 21:8, pages 1982-1992.
Crossref

E.M. DeFilippis, S.R. Feldman & W.W. Huang. (2015) The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. British Journal of Dermatology 172:6, pages 1487-1497.
Crossref

Jeremiah Miller, Brad A. Yentzer, Adele Clark, Joseph L. Jorizzo & Steven R. Feldman. (2010) Pyoderma gangrenosum: A review and update on new therapies. Journal of the American Academy of Dermatology 62:4, pages 646-654.
Crossref

Vimal Prajapati, Jeremy Man & Alain Brassard. (2009) Pyoderma Gangrenosum: Common Pitfalls in Management and a Stepwise, Evidence-Based, Therapeutic Approach. Journal of Cutaneous Medicine and Surgery 13:3_suppl, pages S2-S11.
Crossref

Robert Verburg, Pierre Zelissen, Aniki Rothova, Peter D. Siersema & Bas Oldenburg. (2008) Anti-TNFα therapy in a rare case of Crohnʼs disease: still a Panacea. Inflammatory Bowel Diseases 14:10, pages 1457-1460.
Crossref

B. Díaz-Ley, G. Guhl & J. Fernández-Herrera. (2007) Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumab. Actas Dermo-Sifiliográficas 98:10, pages 657-678.
Crossref

Pascal Juillerat, Stephanie Christen-Zäch, François-Xavier Troillet, Suzanne Gallot-Lavallée, Renato G. Pannizzon & Pierre Michetti. (2007) Infliximab for the Treatment of Disseminated Pyoderma Gangrenosum Associated with Ulcerative Colitis. Dermatology 215:3, pages 245-251.
Crossref

Julia E. Graves, Kara Nunley & Michael P. Heffernan. (2007) Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). Journal of the American Academy of Dermatology 56:1, pages e55-e79.
Crossref

B. Díaz-Ley, G. Guhl & J. Fernández-Herrera. (2007) Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 1: Infliximab and Adalimumab. Actas Dermo-Sifiliográficas (English Edition) 98:10, pages 657-678.
Crossref

Mary Jo. J. Kerns, Julia E. Graves, David I. Smith & Michael P. Heffernan. (2006) Off-Label Uses of Biologic Agents in Dermatology: A 2006 Update. Seminars in Cutaneous Medicine and Surgery 25:4, pages 226-240.
Crossref

Arthur Barrie & Scott Plevy. (2006) Treatment of Immune-Mediated Extraintestinal Manifestations of Inflammatory Bowel Disease with Infliximab. Gastroenterology Clinics of North America 35:4, pages 883-893.
Crossref

Brian J. Nickoloff, Brian K. Bonish, Deborah J. Marble, Kellean A. Schriedel, Luisa A. DiPietro, Kenneth B. Gordon & Mark W. Lingen. (2006) Lessons Learned from Psoriatic Plaques Concerning Mechanisms of Tissue Repair, Remodeling, and Inflammation. Journal of Investigative Dermatology Symposium Proceedings 11:1, pages 16-29.
Crossref

Brian J. Nickoloff & Seth R. Stevens. (2006) What have we learned in dermatology from the biologic therapies?. Journal of the American Academy of Dermatology 54:3, pages S143-S151.
Crossref

Mark Lebwohl & Elizabeth H.Z. Thompson. (2006) Introduction. Journal of the American Academy of Dermatology 54:3, pages S65-S66.
Crossref

Noah Scheinfeld. 2006. TNF-alpha Inhibitors. TNF-alpha Inhibitors 83 99 .

Andrew F. Alexis & Bruce E. Strober. (2016) Off-Label Dermatologic Uses of Anti-TNF-a Therapies. Journal of Cutaneous Medicine and Surgery 9:6, pages 296-302.
Crossref

L B Trost & J K McDonnell. (2005) Important cutaneous manifestations of inflammatory bowel disease. Postgraduate Medical Journal 81:959, pages 580-585.
Crossref

M.R. Kaur & H.M. Lewis. (2005) Severe recalcitrant pyoderma gangrenosum treated with infliximab. British Journal of Dermatology 153:3, pages 689-691.
Crossref

Jörg Reichrath, Guido Bens, Anette Bonowitz & Wolfgang Tilgen. (2005) Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients. Journal of the American Academy of Dermatology 53:2, pages 273-283.
Crossref

Dorothee S. Stichweh, Marilynn Punaro & Virginia Pascual. (2005) Dramatic Improvement of Pyoderma Gangrenosum with Infliximab in a Patient with PAPA Syndrome. Pediatric Dermatology 22:3, pages 262-265.
Crossref

Dana Kazlow Stern, Jackie M. Tripp, Vincent C. Ho & Mark Lebwohl. (2005) The Use of Systemic Immune Moderators in Dermatology: An Update. Dermatologic Clinics 23:2, pages 259-300.
Crossref

Pascal Juillerat, Christian Mottet, Florian Froehlich, Christian Felley, John-Paul Vader, Bernard Burnand, Jean-Jacques Gonvers & Pierre Michetti. (2005) Extraintestinal Manifestations of Crohn’s Disease. Digestion 71:1, pages 31-36.
Crossref

Angela Ehling, Sigrid Karrer, Frank Klebl, Andreas Schäffler & Ulf Müller‐Ladner. (2004) Therapeutic management of pyoderma gangrenosum. Arthritis & Rheumatism 50:10, pages 3076-3084.
Crossref

Aditya K. Gupta & Alayne R. Skinner. (2016) A Review of the Use of Infliximab to Manage Cutaneous Dermatoses. Journal of Cutaneous Medicine and Surgery 8:2, pages 77-89.
Crossref

M. Singh, S. M. Andrew & J. T. Lear. (2004) Infliximab as a treatment for recalcitrant pyoderma gangrenosum. Clinical and Experimental Dermatology 29:2, pages 196-197.
Crossref

Samuel L Gettler, Marti J Rothe, Caron Grin & Jane M Grant-Kels. (2003) Optimal Treatment of Pyoderma Gangrenosum. American Journal of Clinical Dermatology 4:9, pages 597-608.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Favorable Response to Infliximab Treatment in a Patient with Active Crohn Disease and Pyoderma Gangrenosum

Articles from other publishers (29)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature